Tamoxifen is a moderate CYP2C8 inhibitor (Walsky et al, 2005), a CYP2C9 substrate (Jin et al, 2005), and significantly inhibits CYP2C9 activity in breast cancer patients (Boruban et al, 2006). This evidence concerns the gene CYP2C9 and breast cancer.